세계의 전신 마취제 시장 - 규모, 점유율, 동향 분석 보고서 : 약물별, 투여 경로별, 최종 용도별, 용도별, 지역별, 부문 예측(2025-2030년)

General Anesthesia Drugs Market Size, Share & Trends Analysis Report By Drug (Propofol), By Route Of Administration (Intravenous), By End-use (Hospitals), By Application, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

전신 마취제 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 전신 마취제 시장 규모는 2030년까지 65억 6,000만 달러에 이르며, 2025-2030년 동안 3.68%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다. 이러한 예측 성장은 수술량 증가, 마취기술 진보, 만성질환 유병률 증가, 정부 지원책 등 몇 가지 중요한 요인에 의해 야기됩니다. 세계보건기구(WHO)는 의료 접근성 향상과 선택적 수술과 긴급 수술 증가로 수술 건수가 증가하고 있는 것으로 추정하고 있습니다. 2022년만으로도 세계 전체에서 약 2,000만명의 신규 암 환자와 970만명의 암 관련 사망이 발생하고 있어 외과적 개입이 급증하고 있는 것이 부각되고 있습니다. 이러한 수술 증가는 수술 중 환자의 안전과 편안함을 보장하는 데 필수적인 전신 마취 수요 증가에 박차를 가하고 있습니다.

의료 접근을 확대하고 인프라를 개선하기 위한 정부의 이니셔티브는 시장 성장을 더욱 강화하고 있습니다. 북미와 유럽을 포함한 많은 지역에서는 의료 개혁과 자금 지원으로 외과 수술 서비스의 가용성이 높아지고 의료 품질이 향상되었습니다. 예를 들어 미국에서는 '의료비 부담 적정화법(Affordable Care Act)'이 시행되어 기타 국가에서도 비슷한 노력이 이루어지고 있기 때문에 수술에 대한 접근이 확대되어 전신 마취제 수요 증가로 이어지고 있습니다. 의료 인프라와 새로운 의료 시설에 대한 투자는 마취 시장을 강화합니다.

마취의 기술적 진보는 시장 성장에 중요한 역할을 합니다. 표적제어 점적 시스템, 안전성 프로파일을 개선한 새로운 마취제, 모니터링 기술 강화 등의 혁신은 마취의 효율성과 효능에 기여하고 있습니다. 예를 들어, 더 빠른 마취 시작 시간과 회복 시간을 가진 마취제의 개발은 환자의 결과를 개선하고 수요를 견인합니다.

전신 마취제 시장 보고서 하이라이트

• 2024년에는 프로포폴 부문이 25.52%의 대폭적인 점유율로 시장을 석권해 예측기간 중 가장 빠른 CAGR을 나타낼 전망입니다. 프로포폴은 환자의 편안함과 절차의 효율성을 높이는 신속한 발현과 신속한 회복 시간으로 유명합니다.
• 정맥내 부문은 2024년 최대 수익 점유율을 차지하며 예측 기간 동안 CAGR도 3.9%로 가장 빠른 성장이 예상됩니다.
• 2024년에는 인공 슬관절 치환술과 인공 고관절 치환술 부문이 시장을 독점하여 상당한 수익 점유율을 얻었습니다. 이 이점은 골관절염의 유병률 증가, 수술 기술의 진보, 인구 동향에 의해 초래됩니다.
• 2024년에는 병원 부문이 시장을 독점하여 67.05%의 상당한 수익 점유율을 획득했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 전신 마취제 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 전신 마취제 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 전신 마취제 시장 : 약제별, 추정·동향 분석

• 세계의 전신 마취제 시장 :약제 대시보드
• 세계의 전신 마취제 시장 :약제 변동 분석
• 세계의 전신 마취제 시장 :약제 변동 분석
• 세보프루렌
• 프로포폴
• 덱스메데토미딘
• 레미펜타닐
• 데스플루란
• 미다졸람
• 기타

제5장 전신 마취제 시장 : 투여 경로별, 추정·동향 분석

• 세계의 전신 마취제 시장 : 투여 경로 대시보드
• 세계의 전신 마취제 시장 : 투여 경로 변동 분석
• 투여 경로별 수익
• 정맥내
• 흡입

제6장 전신 마취제 시장 : 최종 용도별, 추정·동향 분석

• 세계의 전신 마취제 시장 : 최종 용도 대시보드
• 세계의 전신 마취제 시장 : 최종 용도 변동 분석
• 최종 용도별, 수익
• 병원
• 외래수술센터(ASC)
• 기타

제7장 전신 마취제 시장 : 용도별, 추정·동향 분석

• 세계의 전신 마취제 시장 :용도 대시보드
• 세계의 전신 마취제 시장 :용도 변동 분석
• 용도별 수익
• 심장 수술
• 암
• 일반 수술
• 인공 슬관절 치환술 및 인공 고관절 치환술
• 기타

제8장 전신 마취제 시장 : 약제, 투여 경로, 최종 용도, 용도에 따른 지역별, 추정·동향 분석

• 지역 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 기업/경쟁의 분류
• 벤더 상황
  • 주요 리셀러와 채널 파트너 목록
  • 주요 기업의 시장 점유율 분석, 2024년
  • Baxter International Inc.
  • AstraZeneca
  • AbbVie Inc.
  • B. Braun Melsungen AG
  • Fresenius SE &Co. KgaA
  • Pfizer
  • Hospira Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikama Pharmaceuticals plc
  • Abbott Laboratories

JHS

영문 목차

영문목차

General Anesthesia Drugs Market Growth & Trends:

The global general anesthesia drugs market size is projected to reach USD 6.56 billion by 2030, and projected to grow at a CAGR of 3.68% from 2025 to 2030, according to a new report by Grand View Research, Inc. This projected growth is driven by several critical factors, including increasing surgical volumes, advancements in anesthesia technology, rising prevalence of chronic diseases, and supportive government initiatives. The World Health Organization (WHO) estimates that the volume of surgeries is increasing due to greater access to healthcare and the growing number of elective and emergency procedures. In 2022 alone, there were nearly 20 million new cancer cases and 9.7 million cancer-related deaths globally, highlighting the surge in surgical interventions required. This increase in surgical activity is fueling a heightened demand for general anesthesia, as it is crucial for ensuring patient safety and comfort during operations.

Government initiatives to expand healthcare access and improve infrastructure further support market growth. In many regions, including North America and Europe, healthcare reforms and funding are increasing the availability of surgical services and improving the quality of care. For instance, the U.S. Affordable Care Act and similar initiatives in other countries are expanding surgery access, contributing to the higher demand for general anesthesia drugs. Investments in healthcare infrastructure and new healthcare facilities enhance the anesthesia market.

Technological advancements in anesthesia play a significant role in market growth. Innovations such as target-controlled infusion systems, new anesthetic agents with improved safety profiles, and enhanced monitoring technologies contribute to the efficiency and effectiveness of anesthesia. For instance, developing anesthetics with faster onset and recovery times improves patient outcomes and drives demand.

General Anesthesia Drugs Market Report Highlights:

• In 2024, the propofol segment dominated the market with a substantial share of 25.52% and is also expected to grow at the fastest CAGR during the forecast period. Propofol is renowned for its rapid onset and quick recovery times, which enhance patient comfort and procedural efficiency.
• The intravenous (IV) segment held the largest revenue share in 2024 and is also expected to grow at the fastest CAGR of 3.9% during the forecast period.
• In 2024, the knee and hip replacements segment dominated the market, capturing a substantial revenue share. This dominance is driven by the increasing prevalence of osteoarthritis, advancements in surgical techniques, and demographic trends.
• In 2024, the hospitals segment dominated the market, capturing a substantial revenue share of 67.05%.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Route of Administration
  • 1.2.3. End Use
  • 1.2.4. Application
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Outlook
  • 2.2.2. Route of Administration
  • 2.2.3. End Use
  • 2.2.4. Application
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. General Anesthesia Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Volume of Surgical Procedures
    • 3.2.1.2. Advancements In Anesthesia Technology
    • 3.2.1.3. Regulatory Developments
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory and Compliance Challenges
    • 3.2.2.2. Adverse Effects and Safety Concerns
• 3.3. General Anesthesia Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. General Anesthesia Drugs Market: Drug Estimates & Trend Analysis

• 4.1. Global General Anesthesia Drugs Market: Drug Dashboard
• 4.2. Global General Anesthesia Drugs Market: Drug Movement Analysis
• 4.3. Global General Anesthesia Drugs Market by Drug, Revenue
• 4.4. Sevoflurane
  • 4.4.1. Sevoflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Propofol
  • 4.5.1. Propofol market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Dexmedetomidine
  • 4.6.1. Dexmedetomidine market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Remifentanil
  • 4.7.1. Remifentanil market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Desflurane
  • 4.8.1. Desflurane market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Midazolam
  • 4.9.1. Midazolam market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Others
  • 4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. General Anesthesia Drugs Market: Route of Administration Estimates & Trend Analysis

• 5.1. Global General Anesthesia Drugs Market: Route of Administration Dashboard
• 5.2. Global General Anesthesia Drugs Market: Route of Administration Movement Analysis
• 5.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
• 5.4. Intravenous
  • 5.4.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Inhaled
  • 5.5.1. Inhaled market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. General Anesthesia Drugs Market: End Use Estimates & Trend Analysis

• 6.1. Global General Anesthesia Drugs Market: End Use Dashboard
• 6.2. Global General Anesthesia Drugs Market: End Use Movement Analysis
• 6.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Ambulatory Surgical Centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. General Anesthesia Drugs Market: Application Estimates & Trend Analysis

• 7.1. Global General Anesthesia Drugs Market: Application Dashboard
• 7.2. Global General Anesthesia Drugs Market: Application Movement Analysis
• 7.3. Global General Anesthesia Drugs Market Estimates and Forecasts, By Application, Revenue (USD Million)
• 7.4. Heart Surgeries
  • 7.4.1. Heart Surgeries market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Cancer
  • 7.5.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. General Surgery
  • 7.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Knee and hip replacements
  • 7.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other
  • 7.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. General Anesthesia Drugs Market: Regional Estimates & Trend Analysis by Drug, Route of Administration, End Use and Application

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key company market share analysis, 2024
  • 9.2.3. Baxter International Inc.
    • 9.2.3.1. Company overview
    • 9.2.3.2. Financial performance
    • 9.2.3.3. Drug benchmarking
    • 9.2.3.4. Strategic initiatives
  • 9.2.4. AstraZeneca
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Drug benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. AbbVie Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Drug benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. B. Braun Melsungen AG
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Drug benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Fresenius SE & Co. KgaA
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Drug benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Pfizer
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Drug benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Hospira Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Drug benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Aspen Pharmacare Holdings Limited
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Drug benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Hikama Pharmaceuticals plc
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Drug benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Abbott Laboratories
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Drug benchmarking
    • 9.2.12.4. Strategic initiatives

관련자료